Adrenocortical Carcinoma Market to Rise by 2034 | Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech, and others are expected to boost the market

DelveInsight's "Adrenocortical Carcinoma Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Adrenocortical Carcinoma, historical and forecasted epidemiology as well as the Adrenocortical Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Adrenocortical Carcinoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Adrenocortical Carcinoma market size from 2034 to 2034, segmented by seven major markets. The Report also covers current Adrenocortical Carcinoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Adrenocortical Carcinoma market.

Request for a Free Sample Report @ https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key highlights from the adrenocortical carcinoma market report:

The market for Adrenocortical Carcinoma (ACC) in the seven major markets (7MM) is projected to experience significant growth at a robust CAGR from 2024 to 2034. This expansion is driven by an increasing number of incident cases, the introduction of new therapies, and heightened awareness of ACC.
According to DelveInsight analysts, approximately 27% of all ACC cases in the 7MM are expected to originate from the United States. In 2023, the EU4 and the UK collectively reported around 600 new cases of ACC.
In the 7MM, the market is primarily composed of adjuvant therapies, particularly Mitotane (with or without Streptozotocin), which generated nearly USD 3.69 million in 2023.
The overall market size for ACC treatment is anticipated to grow during the forecast period, fueled by the emergence of new and effective therapies such as EO2401 combined with Nivolumab, among others.

Adrenocortical Carcinoma Overview
Adrenocortical carcinoma (ACC) is a rare but aggressive cancer that originates in the adrenal cortex, the outer layer of the adrenal glands. These glands are located on top of each kidney and produce various hormones that regulate metabolism, immune response, and blood pressure. ACC can be functional (producing excess hormones) or non-functional.

Causes

The exact causes of ACC are not well understood, but several factors may increase the risk:

1. Genetic Conditions:
- Li-Fraumeni Syndrome: A hereditary condition associated with a higher risk of several cancers.
- Beckwith-Wiedemann Syndrome: A growth disorder that can lead to tumors.
- Multiple Endocrine Neoplasia (MEN) Syndrome: Particularly MEN1.

2. Age and Gender: ACC is more common in adults, typically between the ages of 40 and 60, and is slightly more prevalent in women.

3. Hormonal Factors: Increased levels of certain hormones may play a role, though the connection is not fully understood.

Signs and Symptoms

Symptoms of ACC can vary based on whether the tumor is functional or non-functional:

- Functional ACC:
- Excess cortisol can lead to Cushing's syndrome (weight gain, moon face, easy bruising).
- Increased androgen production can cause symptoms such as hirsutism (excessive hair growth) and menstrual irregularities.
- Elevated aldosterone levels may cause high blood pressure and low potassium levels.

- Non-Functional ACC:
- Abdominal pain or discomfort.
- A palpable mass or lump in the abdomen.
- Unexplained weight loss.
- Fatigue and weakness.

Diagnosis

1. Imaging Studies:
- CT Scan or MRI: Used to visualize the adrenal glands and assess the tumor's size and spread.
- PET Scan: May help evaluate metastasis.

2. Hormonal Testing:
- Blood and urine tests to measure hormone levels (cortisol, aldosterone, and androgens) to determine if the tumor is functional.

3. Biopsy:
- Fine needle aspiration or surgical biopsy may be performed to obtain tissue samples for histological examination.

Treatment Options

1. Surgery:
- Adrenalectomy: The primary treatment for localized ACC is the surgical removal of the adrenal gland, often along with surrounding tissue and lymph nodes.

2. Chemotherapy:
- Post-surgery chemotherapy may be recommended for high-risk patients or those with metastatic disease to reduce the risk of recurrence.

3. Radiation Therapy:
- May be used in cases where surgery is not possible or as an adjunct to surgery for residual disease.

4. Targeted Therapy:
- Drugs such as mitotane may be used to treat advanced ACC. Mitotane works by inhibiting adrenal function and may help shrink tumors.

5. Clinical Trials:
- Participation in clinical trials may be an option for patients with advanced ACC, as new therapies and combinations are continually being investigated.

Follow-Up and Prognosis

Regular follow-up is essential to monitor for recurrence or metastasis. The prognosis for ACC can vary significantly based on factors such as tumor size, stage at diagnosis, and whether the tumor is functional or non-functional. Early detection and treatment are critical for improving outcomes.

Learn more about Adrenocortical Carcinoma, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/report-store/adrenocortical-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Adrenocortical Carcinoma Market

The Adrenocortical Carcinoma market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Adrenocortical Carcinoma market trends by analyzing the impact of current Adrenocortical Carcinoma therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

According to DelveInsight, the Adrenocortical Carcinoma market in 7MM is expected to witness a major change in the study period 2034-2034.

The market for Adrenocortical Carcinoma (ACC) is poised for positive growth with the anticipated approval of new treatments like EO2401 combined with Nivolumab, among others. In 2023, the total market size for ACC in the seven major markets (7MM) was approximately USD 22.4 million, with expectations for significant growth throughout the forecast period.
Within the 7MM, the United States held the largest market share in 2023, accounting for nearly 47%. The EU4 and the UK together generated an estimated USD 8.2 million, with expectations for substantial growth at a robust CAGR. Among European countries, Germany led the market share in 2023, followed by the UK and France, while Spain represented the smallest market share.
Japan contributed approximately 16% to the total ACC market in 2023, with projections indicating strong growth at a considerable CAGR during the study period.

Request a sample and discover more about the report offerings at:
https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Adrenocortical Carcinoma Epidemiology

Among the EU4 countries and the UK, Germany reported the highest number of incident cases of Adrenocortical Carcinoma (ACC), with approximately 160 cases in 2023. Conversely, Spain had the lowest incidence within this group for the same year.
In Japan, there were around 200 new cases of ACC in 2023, with expectations for significant growth at a robust CAGR.
ACC cases are categorized into four distinct stages. In the US, the distribution reveals that Stage III accounts for the highest percentage of cases at 38%, followed by Stage IV at 27%, Stage II at 20%, and Stage I at 15%.
Gender-specific data within the 7MM shows that approximately 40% of ACC cases occur in males, while 60% occur in females.
The highest proportion of ACC cases in the EU4 and the UK was found in individuals aged 41-60 years (53%), whereas the age group under 20 years had the fewest cases, accounting for only 3%.

Explore more about Adrenocortical Carcinoma Epidemiology at: https://www.delveinsight.com/report-store/adrenocortical-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Adrenocortical Carcinoma Marketed Drugs

LYSODREN (Mitotane): HRA Pharma/Bristol-Myers Squibb

Adrenocortical Carcinoma Emerging Drugs

EO2401 + Nivolumab: Enterome/Bristol-Myers Squibb

Request for a sample report to understand more about the Adrenocortical Carcinoma pipeline development activities at: https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Adrenocortical Carcinoma Therapeutics Assessment

Major key companies such as Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech, and others are working proactively in the Adrenocortical Carcinoma Therapeutics market to develop novel therapies which will drive the Adrenocortical Carcinoma treatment markets in the upcoming years.

Learn more about the emerging therapies & key companies at: https://www.delveinsight.com/report-store/adrenocortical-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Adrenocortical Carcinoma Report Key Insights

1. Adrenocortical Carcinoma Patient Population
2. Adrenocortical Carcinoma Market Size and Trends
3. Key Cross Competition in the Adrenocortical Carcinoma Market
4. Adrenocortical Carcinoma Market Dynamics (Key Drivers and Barriers)
5. Adrenocortical Carcinoma Market Opportunities
6. Adrenocortical Carcinoma Therapeutic Approaches
7. Adrenocortical Carcinoma Pipeline Analysis
8. Adrenocortical Carcinoma Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Adrenocortical Carcinoma Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Adrenocortical Carcinoma Competitive Intelligence Analysis
4. Adrenocortical Carcinoma Market Overview at a Glance
5. Adrenocortical Carcinoma Disease Background and Overview
6. Adrenocortical Carcinoma Patient Journey
7. Adrenocortical Carcinoma Epidemiology and Patient Population
8. Adrenocortical Carcinoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Adrenocortical Carcinoma Unmet Needs
10. Key Endpoints of Adrenocortical Carcinoma Treatment
11. Adrenocortical Carcinoma Marketed Products
12. Adrenocortical Carcinoma Emerging Therapies
13. Adrenocortical Carcinoma Seven Major Market Analysis
14. Attribute Analysis
15. Adrenocortical Carcinoma Market Outlook (7 major markets)
16. Adrenocortical Carcinoma Access and Reimbursement Overview
17. KOL Views on the Adrenocortical Carcinoma Market
18. Adrenocortical Carcinoma Market Drivers
19. Adrenocortical Carcinoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Adrenocortical Carcinoma Market report here: https://www.delveinsight.com/report-store/adrenocortical-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Us:

Kritika Rehani
info@delveinsight.com
+14699457679
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.